Antitumor activity and safety of camrelizumab combined with apatinib in patients with relapsed or refractory peripheral T-cell lymphoma: An open-label, multicenter, phase II study

INTRODUCTION: The treatment for relapsed/refractory peripheral T-cell lymphoma (r/r PTCL) is suboptimal. This open-label, multicenter, single-arm study aimed to investigate the antitumor activity and safety of camrelizumab (a PD-1 blockade) plus apatinib (an antiangiogenic agent) for patients with r...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Yanfei, Song, Yuqin, Zuo, Shubo, Zhang, Xian, Liu, Hui, Wang, Jingwen, Wang, Jingbo, Tang, Yongjing, Zheng, Wen, Ying, Zhitao, Ping, Lingyan, Zhang, Chen, Wu, Meng, Zhu, Jun, Xie, Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10111014/
https://www.ncbi.nlm.nih.gov/pubmed/37081867
http://dx.doi.org/10.3389/fimmu.2023.1128172

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10111014/
https://www.ncbi.nlm.nih.gov/pubmed/37081867
http://dx.doi.org/10.3389/fimmu.2023.1128172

Ejemplares similares